Scarica l'app Stockscreener
88.51
0.24%
-0.21
Dopo l'orario di chiusura:
88.51
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BPMC Giù?
Forum
Previsione
Precedente Chiudi:
$88.72
Aprire:
$86.82
Volume 24 ore:
1.29M
Relative Volume:
1.41
Capitalizzazione di mercato:
$5.49B
Reddito:
$434.41M
Utile/perdita netta:
$-128.05M
Rapporto P/E:
-41.95
EPS:
-2.11
Flusso di cassa netto:
$-250.52M
1 W Prestazione:
-7.10%
1M Prestazione:
-8.35%
6M Prestazione:
-4.31%
1 anno Prestazione:
-6.69%
Intervallo 1D:
$85.35
$88.74
Intervallo di 1 settimana:
$85.35
$95.30
Portata 52W:
$80.67
$121.90
Blueprint Medicines Corp Stock (BPMC) Company Profile
Nome
Blueprint Medicines Corp
Settore
Industria
Telefono
617-374-7580
Indirizzo
45 SIDNEY STREET, CAMBRIDGE, MA
Confronta BPMC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BPMC
Blueprint Medicines Corp
|
88.51 | 5.49B | 434.41M | -128.05M | -250.52M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Blueprint Medicines Corp Stock (BPMC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-20 | Ripresa | Morgan Stanley | Equal-Weight |
| 2025-03-18 | Iniziato | Wolfe Research | Outperform |
| 2025-03-17 | Iniziato | Jefferies | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-11-14 | Iniziato | JP Morgan | Overweight |
| 2024-10-24 | Iniziato | UBS | Neutral |
| 2024-05-14 | Iniziato | Stephens | Overweight |
| 2024-05-06 | Aggiornamento | Leerink Partners | Underperform → Market Perform |
| 2023-10-27 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-08-21 | Reiterato | Needham | Buy |
| 2023-07-31 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-06-05 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2023-01-03 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | Iniziato | Needham | Buy |
| 2022-11-02 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-09-14 | Iniziato | Berenberg | Buy |
| 2022-07-08 | Iniziato | Oppenheimer | Outperform |
| 2022-06-27 | Iniziato | Wells Fargo | Underweight |
| 2022-06-10 | Downgrade | Citigroup | Neutral → Sell |
| 2022-06-01 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-03-01 | Iniziato | Citigroup | Neutral |
| 2022-02-17 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-01-25 | Aggiornamento | Stifel | Hold → Buy |
| 2021-11-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-09-30 | Ripresa | Stifel | Hold |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-03-31 | Iniziato | Credit Suisse | Neutral |
| 2020-12-03 | Iniziato | Stifel | Hold |
| 2020-11-02 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-02 | Downgrade | Jefferies | Buy → Hold |
| 2020-10-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-15 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-05 | Iniziato | Barclays | Equal Weight |
| 2020-03-17 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-28 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-27 | Iniziato | BMO Capital Markets | Market Perform |
| 2019-11-06 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2019-10-22 | Iniziato | JMP Securities | Mkt Outperform |
| 2019-10-03 | Iniziato | H.C. Wainwright | Buy |
| 2019-09-12 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-08-29 | Iniziato | Piper Jaffray | Neutral |
| 2019-08-15 | Ripresa | Raymond James | Mkt Perform |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2019-05-23 | Ripresa | Goldman | Buy |
| 2019-04-03 | Iniziato | Morgan Stanley | Overweight |
| 2018-09-25 | Iniziato | Leerink Partners | Outperform |
| 2017-12-11 | Reiterato | Goldman | Buy |
Mostra tutto
Blueprint Medicines Corp Borsa (BPMC) Ultime notizie
Exclusive: Blueprint Medicines Leadership Takes Center Stage at Major Healthcare Conference - Stock Titan
Is Blueprint Medicines (BPMC) One of the Best Mid Cap Biotech Stocks to Buy? - Insider Monkey
Blueprint Medicines at H.C. Wainwright Conference: Strategic Pipeline Expansion - Investing.com
Blueprint Medicines at H.C. Wainwright Conference: Strategic Pipeline Expansion By Investing.com - Investing.com UK
Blueprint Medicines COO Christina Rossi sells shares worth $216,075 - Investing.com India
Is Blueprint Medicines Corporation (BPMC) a Promising Biotech Stock According to Wall Street Analysts - Yahoo Finance
PNC Financial Services Group Inc. Boosts Stake in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Proficio Capital Partners LLC Makes New $1.01 Million Investment in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Blueprint Medicines Co. (NASDAQ:BPMC) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
The Analyst Verdict: Blueprint Medicines In The Eyes Of 14 Experts - Benzinga
Blueprint Medicines (BPMC): Among Stocks Insiders Are Selling In March - Insider Monkey
Morgan Stanley sets Blueprint Medicines stock at Equalweight, $100 target - Investing.com
Morgan Stanley sets Blueprint Medicines stock at Equalweight, $100 target By Investing.com - Investing.com UK
Blueprint Medicines’ SWOT analysis: stock poised for growth amid challenges - Investing.com
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Victory Capital Management Inc. - Defense World
Wolfe Research initiates Blueprint Medicines with Outperform rating - Investing.com
Blueprint Medicines (NASDAQ:BPMC) Now Covered by Jefferies Financial Group - Defense World
This Blueprint Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
241,966 Shares in Blueprint Medicines Co. (NASDAQ:BPMC) Purchased by Raymond James Financial Inc. - Defense World
Blueprint Medicines initiated with a Buy at Jefferies - TipRanks
Jefferies sets Blueprint Medicines stock Buy rating, $135 target - Investing.com
Jefferies sets Blueprint Medicines stock Buy rating, $135 target By Investing.com - Investing.com Philippines
Blueprint Medicines (NASDAQ:BPMC) Shares Down 1.6% – Here’s Why - Defense World
Blueprint Medicines director Jeffrey Albers sells $658,500 in stock By Investing.com - Investing.com Australia
Steward Partners Investment Advisory LLC Lowers Position in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Blueprint Medicines director Jeffrey Albers sells $658,500 in stock - Investing.com India
Charles Schwab Investment Management Inc. Purchases 7,165 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Blueprint Medicines’ SWOT analysis: strong Ayvakit sales drive stock outlook By Investing.com - Investing.com South Africa
Blueprint Medicines’ SWOT analysis: strong Ayvakit sales drive stock outlook - Investing.com
US Bancorp DE Sells 1,988 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Blueprint Medicines Co. (NASDAQ:BPMC) Stock Holdings Lifted by Bank of New York Mellon Corp - Defense World
Blueprint Medicines (NASDAQ:BPMC) Coverage Initiated at Scotiabank - Defense World
Blueprint Medicines CFO sells shares worth $469,219 By Investing.com - Investing.com South Africa
Proficio Capital Partners LLC Purchases Shares of 11,600 Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Blueprint Medicines CEO sells $1.43 million in stock By Investing.com - Investing.com Australia
Zacks Research Has Positive Outlook for BPMC Q1 Earnings - Defense World
Blueprint Medicines Stock: Executives Sell Shares Amid Growth - sharewise
Blueprint Medicines CMO Hewes L. Becker sells $890k in stock - Investing.com Canada
Blueprint Medicines EVP sells shares worth $467,265 By Investing.com - Investing.com South Africa
Blueprint Medicines CEO sells $1.43 million in stock - Investing.com
Blueprint Medicines EVP sells shares worth $467,265 - Investing.com India
Blueprint Medicines chief commercial officer Lee Philina sells $331,490 in stock - Investing.com
Blueprint Medicines CFO sells shares worth $469,219 - Investing.com
Blueprint Medicines Executives Sell Shares to Cover Tax Obligations - TradingView
Upward Trajectory: Blueprint Medicines Corp (BPMC) Posts a Slidee, Closing at 88.54 - The Dwinnex
Scotiabank sets Blueprint Medicines stock target at $150 - Investing.com
Blueprint Medicines Corp. to Host Earnings Call - ACCESS Newswire
Truist Financial Corp Makes New Investment in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Blueprint Medicines Corp Azioni (BPMC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.05%
1.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):